New handheld chip targets TP53 in CLL

[Guest guest]

In this study of 98 untreated CLL patients, researchers used the AmpliChip p53

research microarray and direct sequencing and performed microarrays analysis on

TP53 mutated and/or deleted (17p-) cases.

Detection of TP53 mutations by the AmpliChip was associated with a significantly

worse survival. Comparison of the array and direct sequencing tests showed that

the p53 test detected more mutations, although it failed to identify two

micro-deletions, so it isn't perfect yet.

This a joint development by Roche and Merck, however will requires extensive

clinical trials and FDA approval.

More: http://cllcanada.ca

Source:Genes, Chromosomes and Cancer; DOI: 10.1002/gcc.20852

~chris